Daewoong Pharmaceutical said Wednesday it has launched Celltrion's Stoboclo (denosumab) in Korea, pricing the biosimilar at 111,384 won ($76.7), 28 percent below Amgen's Prolia, to treat osteoporosis.
Daewoong’s launch of Stoboclo (denosumab) in Korea offers a 28 percent discount to Prolia.
Daewoong’s launch of Stoboclo (denosumab) in Korea offers a 28 percent discount to Prolia.
This follows Celltrion’s announcement to offer its own Prolia biosimilar at a similarly low price to improve accessibility without health insurance coverage, dubbed the “local price of eight hamburgers.”
The one-injection, six-month treatment is indicated for postmenopausal osteoporosis and skeletal-related complications in patients with bone metastasis, designed to boost patient adherence while reducing hospital visits.
Stoboclo also features an auto-retracting needle for safer administration and a latex-free cap for patient sensitivity. Daewoong said it will leverage its sales network while collaborating with Celltrion’s biosimilar expertise to drive Stoboclo’s nationwide reach and pursue global market expansion.
Celltrion received approval for the drug from the Ministry of Food and Drug Safety in November 2024 and has secured European Commission and FDA approvals in February 2025.
Related articles
Celltrion wins FDA nod for Prolia and Xgeva biosimilars
Celltrion wins EU nod for Prolia, Xgeva biosimilars to treat osteoporosis
Samsung Bioepis joins denosumab battle with FDA, EU nod as Amgen’s $5.5-bil. stronghold nears patent cliff
[JPM2025] Celltrion will sell cheap biosimilar for osteoporosis prophylaxis. How will original drug maker Amgen respond?